These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 31183847)
1. Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists-Data from a Specialized Coagulation Service. Prochaska JH; Hausner C; Nagler M; Göbel S; Eggebrecht L; Panova-Noeva M; Arnold N; Lauterbach M; Bickel C; Michal M; Hardt R; Espinola-Klein C; Lackner KJ; Münzel T; Wild PS Thromb Haemost; 2019 Aug; 119(8):1347-1357. PubMed ID: 31183847 [TBL] [Abstract][Full Text] [Related]
2. e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study. Prochaska JH; Göbel S; Keller K; Coldewey M; Ullmann A; Lamparter H; Schulz A; Schinzel H; Bickel C; Lauterbach M; Michal M; Hardt R; Binder H; Espinola-Klein C; Lackner KJ; Ten Cate H; Münzel T; Wild PS J Thromb Haemost; 2017 Jul; 15(7):1375-1385. PubMed ID: 28457013 [TBL] [Abstract][Full Text] [Related]
3. Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. Vinding NE; Butt JH; Olesen JB; Xian Y; Kristensen SL; Rørth R; Bonde AN; Gundlund A; Yafasova A; Weeke PE; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL J Am Heart Assoc; 2022 Mar; 11(6):e024402. PubMed ID: 35229642 [TBL] [Abstract][Full Text] [Related]
4. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study. Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984 [TBL] [Abstract][Full Text] [Related]
7. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. Prochaska JH; Göbel S; Keller K; Coldewey M; Ullmann A; Lamparter H; Jünger C; Al-Bayati Z; Baer C; Walter U; Bickel C; ten Cate H; Münzel T; Wild PS BMC Med; 2015 Jan; 13():14. PubMed ID: 25616558 [TBL] [Abstract][Full Text] [Related]
8. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553 [TBL] [Abstract][Full Text] [Related]
9. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854 [TBL] [Abstract][Full Text] [Related]
10. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. Corrochano M; Jiménez B; Millón J; Gich I; Rambla M; Gil E; Caparrós P; Macho R; Souto JC BMC Cardiovasc Disord; 2020 Apr; 20(1):166. PubMed ID: 32276619 [TBL] [Abstract][Full Text] [Related]
11. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973 [TBL] [Abstract][Full Text] [Related]
12. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. Staerk L; Fosbøl EL; Lamberts M; Bonde AN; Gadsbøll K; Sindet-Pedersen C; Holm EA; Gerds TA; Ozenne B; Lip GYH; Torp-Pedersen C; Gislason GH; Olesen JB Eur Heart J; 2018 May; 39(19):1698-1705a. PubMed ID: 29165556 [TBL] [Abstract][Full Text] [Related]
13. Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices - results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment). Mertens C; Siebenhofer A; Berghold A; Pregartner G; Ulrich LR; Mergenthal K; Kemperdick B; Schulz-Rothe S; Rauck S; Harder S; Gerlach FM; Petersen JJ BMC Health Serv Res; 2019 Aug; 19(1):539. PubMed ID: 31370840 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M; Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542 [TBL] [Abstract][Full Text] [Related]
15. Predictors of anticoagulation quality in 15 834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients. Schaefer C; Wuillemin WA; Kessels A; Jacobson A; Nagler M Br J Haematol; 2016 Nov; 175(4):677-685. PubMed ID: 27468696 [TBL] [Abstract][Full Text] [Related]
16. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407 [TBL] [Abstract][Full Text] [Related]
17. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
18. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study. Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V; J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096 [TBL] [Abstract][Full Text] [Related]
19. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622 [TBL] [Abstract][Full Text] [Related]
20. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. Binding C; Bjerring Olesen J; Abrahamsen B; Staerk L; Gislason G; Nissen Bonde A J Am Coll Cardiol; 2019 Oct; 74(17):2150-2158. PubMed ID: 31648707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]